UT MD Anderson joins global consortium committed to eliminating cervical cancer
The University of Texas MD Anderson Cancer Center today announced it has joined a global consortium dedicated to accelerating the elimination of cervical cancer worldwide. The collaboration agreement with the Elimination Partnership in Cervical Cancer (EPICC) expands UT MD Anderson’s global oncology efforts, further strengthening its commitment to advancing cancer prevention and control in medically underserved regions.
The ...
Novel CAR T cell therapy developed by UT MD Anderson researchers moves into clinical studies
The novel therapy targets CD94+ relapsed or refractory T/NK cell lymphomas
UT MD Anderson received Investigational New Drug clearance from the...
Novel tool helps identify key targets to strengthen CAR NK cell therapies
Researchers developed the first genome-wide CRISPR screening tool for primary human natural killer (NK) cells
Study revealed critical regulators...
Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T cell therapy
Largest study of its kind provides new insights on lymphoma biology to guide clinical approaches
Researchers identified three subgroups with differential benefit from CD19 CAR T cell therapy
Study points to opportunities for alternative approaches to treat patients who do not benefit from CAR T cell therapies
HOUSTON, JUNE 18, 2025 ― In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center...
ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
Blastic plasmacytoid dendric cell neoplasm (BPDCN) is a rare, aggressive blood cancer that often involves the bone marrow, skin and, sometimes...
NK cells complexed with bispecific antibody yield high response rates in patients with lymphoma
HOUSTON ― A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/...
ASH: Triplet combination regimens demonstrate high response rates in multiple leukemias
ABSTRACTS: 216, 219, 1011
SAN DIEGO ― Three clinical trials led by researchers from The University of Texas MD Anderson...
ASH: Monoclonal antibody therapy improves survival in cancer-associated hyper-inflammatory disorder
ABSTRACT: 805
SAN DIEGO – Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare...
Novel CAR T cell therapy obe-cel demonstrates high response rates in adult patients with advanced B-cell ALL
Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric...
MD Anderson launches Institute for Cell Therapy Discovery & Innovation to deliver transformational new therapies
The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation,...